Single dose darbepoetin alfa is useful in reducing red cell transfusions in leukemic children receiving chemotherapy

Area of Science:

• Pediatric Oncology
• Hematology
• Pharmacology

Background:

• Chemotherapy-induced anemia (CIA) is a common complication in pediatric cancer patients.
• Erythropoiesis-stimulating agents (ESAs) are increasingly used for CIA in adults, but data in pediatric populations is limited.
• Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, often requiring intensive chemotherapy.

Purpose of the Study:

• To evaluate the efficacy and tolerability of a single-dose of darbepoetin alfa in pediatric ALL patients undergoing induction chemotherapy.
• To compare transfusion requirements in patients receiving darbepoetin alfa versus a historical control group.
• To assess the safety profile of darbepoetin alfa in this pediatric cohort.

Main Methods:

• A prospective study of 35 pediatric ALL patients receiving a single dose of darbepoetin alfa during induction chemotherapy.
• Comparison with a retrospective control group of pediatric ALL patients who did not receive ESAs.
• Data collection on packed red blood cell transfusion requirements and adverse events.

Main Results:

• Patients receiving darbepoetin alfa required significantly fewer packed red blood cell units (0.88 units/patient) compared to controls (2.04 units/patient).
• No major side effects were reported in the group treated with darbepoetin alfa.
• The study suggests a potential benefit of ESAs in reducing transfusion needs for pediatric ALL patients.

Conclusions:

• A single dose of darbepoetin alfa appears effective and well-tolerated for managing chemotherapy-induced anemia in pediatric ALL.
• Further prospective, double-blinded studies are recommended to optimize dosing regimens.
• Investigating ESAs in pediatric solid tumors is also warranted.